However, further research is needed to elucidate the complete molecular pathway from genetic mutations to clinical manifestations, and to better explore insulin signaling abnormalities in DM1 patients, particularly the impact of insulin receptor splice variants on insulin sensitivity and secretion. This evidence concerns the gene INSR and myotonic dystrophy type 1.